

HEPION PHARMACEUTICALS, INC.

PROXY FOR ANNUAL MEETING TO BE HELD ON JUNE 22, 2023
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned hereby appoints, Robert Foster, Ph.D. and John Cavan, and each of them, as proxies, each with full power of substitution, to represent and to vote all the shares of common stock of Hepion Pharmaceuticals, Inc. (the “Company”), which the undersigned would be entitled to vote, at the Company’s Annual Meeting of Stockholders to be held on June 22, 2023 and at any adjournments thereof, subject to the directions indicated on this Proxy Card.

In their discretion, the proxy is authorized to vote upon any other matter that may properly come before the meeting or any adjournments thereof.

THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE SPECIFICATIONS MADE, BUT IF NO CHOICES ARE INDICATED, THIS PROXY WILL BE VOTED FOR THE ELECTION OF ALL NOMINEES AND FOR THE PROPOSALS LISTED BELOW.

This proxy is governed by the laws of the State of Delaware.

IMPORTANT—This Proxy must be signed and dated below.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to Be Held on June 22, 2023 at 9:00 am local time at the Company’s offices located at 399 Thornall Street, First Floor, Edison, NJ 08837. The proxy statement and the 2022 Annual Report on Form 10-K are available at <https://annualgeneralmeetings.com/hepa2023>

THIS IS YOUR PROXY

YOUR VOTE IS IMPORTANT!

Dear Stockholder:

We cordially invite you to attend the Annual Meeting of Stockholders of Hepion Pharmaceuticals, Inc. to be held at the Company’s offices located at 399 Thornall Street, First Floor, Edison, NJ 08837, on June 22, 2023, beginning at 9:00 a.m. local time.

Please read the proxy statement which describes the proposals and presents other important information, and complete, sign and return your proxy promptly in the enclosed envelope.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSALS 1-4

1. Election of Directors

Nominees.	FOR	WITHHOLD		FOR	WITHHOLD
01. Gary S. Jacob, Ph.D.	<input type="checkbox"/>	<input type="checkbox"/>	05. Petrus “Peter” Wijngaard, Ph.D.	<input type="checkbox"/>	<input type="checkbox"/>
02. Robert Foster, Ph.D.	<input type="checkbox"/>	<input type="checkbox"/>	06. Kaouthar Lbiati, M.D.	<input type="checkbox"/>	<input type="checkbox"/>
03. John P. Brancaccio	<input type="checkbox"/>	<input type="checkbox"/>	07. Anand Reddi	<input type="checkbox"/>	<input type="checkbox"/>
04. Timothy Block, Ph.D.	<input type="checkbox"/>	<input type="checkbox"/>			

2. Proposal to ratify BDO USA, LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023.

☐ **FOR** ☐ **AGAINST** ☐ **ABSTAIN**

3. Proposal to approve the Company’s 2023 Omnibus Equity Incentive Plan.

☐ **FOR** ☐ **AGAINST** ☐ **ABSTAIN**

4. Proposal to approve , on an advisory basis, the compensation of the Company’s named executive officers.

☐ **FOR** ☐ **AGAINST** ☐ **ABSTAIN**

Important: Please sign exactly as name appears on this proxy. When signing as attorney, executor, trustee, guardian, corporate officer, etc., please indicate full title.

Date: _____

Signature: _____

Signature: _____

Title: _____

- ☐ I agree to receive all future communications related to these holdings electronically via the email address provided below. I understand I am able to change this selection at any time in the future.

EMAIL ADDRESS: _____